Back to JVIR CME 2017 September
JVIR CME 2017 September 1.00 SA-CME

JVIR CME 2017 September

  • Article: Albumin-Bilirubin (ALBI) and Platelet-Albumin-Bilirubin (PALBI) Grade accurately predict overall survival in high-risk patients undergoing conventional Transarterial Chemoembolization for Hepatocellular Carcinoma
  • Free for SIR members
  • 1 SA-CME credit
  • Expires Sept. 30, 2020
  • Credits:
    1.00 Self-Assessment CME
    1.00 CME
    1.00 Participation
    • List Price: $20.00
    • Member Price: Free
     
    Want to save more?
    Log into see if you qualify for a lower rate.
    Members save $20.00 or more Join
    Item Details:

    This retrospective study evaluates the role of albumin-bilirubin (ALBI) and platelet-albumin-bilirubin (PABLI) grades in predicting overall survival in high-risk patients undergoing conventional transarterial chemoembolization (cTACE) for hepatocellular carcinoma (HCC). This program is designed to...

    Back to JVIR CME 2017 September
    View More View Less

    Text/HTML

    Contact us:
    Physical Products: 888-695-9733 or SIR@brightkey.net
    Electronic Products: 703-460-5590 or enicholson@sirweb.org

    0